MDS Sciex Signs Agreement with SCRUM Inc. to Distribute Innovative Drug Screening Technology for the First Time in Japan
24 Ottobre 2006 - 3:00PM
PR Newswire (US)
TORONTO, Oct. 24 /PRNewswire-FirstCall/ -- MDS Sciex, the
analytical instruments division of MDS Inc. (TSX: MDS; NYSE: MDZ)
and SCRUM Inc., a leading life sciences technology distribution
company in Japan, announced today that they have signed an
exclusive agreement to distribute MDS Sciex's CellKey(TM) system in
Japan. This agreement will make this innovative drug screening
technology accessible to the Japanese biopharmaceutical community
for the first time. The CellKey(TM) system enables researchers to
make better informed decisions earlier during the discovery of new
therapeutics. This system signals a new approach to drug screening
as it provides a label-free, single platform for cellular studies,
with accurate, robust and reproducible results. CellKey(TM)
technology enables the use of endogenous cell receptors - they are
expressed in their natural state - to test new compounds, instead
of using cells that have been genetically manipulated. The system
does not require the luminescent or fluorescent tags that can
adversely affect the response of cells to new compounds. As a
result, it can produce drug screening results with greater
biorelevance. "Japan represents one of the fastest growing markets
in drug discovery," said Andy Boorn, President of MDS Sciex. "SCRUM
Inc. is a well-respected life sciences company capable of providing
extensive sales and support coverage throughout Japan. We are
excited and honored to partner with SCRUM in bringing our novel
CellKey(TM) system to the Japanese biopharmaceutical community for
the first time." "We're proud to announce our partnership with MDS
Sciex, a global leader in analytical instruments," said Hiromichi
Ogawa, President of SCRUM Inc., "We strive to find unique,
innovative products in the world's markets to provide superior drug
discovery solutions to our valued biopharmaceutical customers in
Japan. The CellKey(TM) system is a perfect addition to our
portfolio to meet our customers' changing needs." About the
CellKey(TM) System The CellKey(TM) system is a revolutionary,
functional cell-based assay platform enabling label-free, real-time
analysis of cell surface receptor activity in a single-assay
format. The system's underlying technology is Cellular Dielectric
Spectroscopy (CDS) - an impedance based measurement system that
eliminates the need for tags, dyes, or specialized reagents. The
system was designed to meet the needs of drug discovery scientists
- from target identification and validation through lead
optimization. It is sensitive enough to consistently monitor
ligand-mediated activation of endogenous receptors expressed in
adherent or suspension cell lines and primary cells. The benefit of
this is the ability to generate more physiologically relevant data
than obtained when using genetically and chemically manipulated
cells. The Cellkey(TM) platform package is a fully integrated
solution comprised of the instrument with on-board temperature
control and fluidics, and an extensive software suite to manage the
information-rich, real-time kinetic data generated. About MDS Sciex
and MDS Inc. MDS Sciex is the scientific instrumentation and
technology solutions division of MDS Inc. MDS Inc.
(TSX:MDS)(NYSE:MDZ) has more than 8,800 highly skilled people in 28
countries. It provides a diverse range of superior products and
services to increase customers' speed, precision and productivity
in the drug development and disease diagnosis processes. MDS is a
global, values-driven life sciences company, recognized for its
reliability and collaborative relationships that help create better
outcomes in the treatment of disease. Find out more at
http://www.mdsinc.com/ or by calling 1-888-MDS-7222, 24 hours a
day. About SCRUM Inc. SCRUM brings superior value from around the
world to Japan's pharmaceutical companies, diagnostic companies,
universities, national institutions, and other commercial
biotechnology entities. SCRUM is organized to provide professional
services (including custom antibody development) to customers with
a team of highly skilled scientists, engineers, and marketing and
sales experts. Key members of SCRUM's management team have over 15
years experience in life science business. SCRUM is ISO9001
certified, and the company is constantly striving for complete
customer satisfaction. Find out more at
http://www.scrum-net.co.jp/. CellKey(TM) is a trademark of MDS
Inc., through its MDS Sciex Division. DATASOURCE: MDS Inc. CONTACT:
For Investors, Sharon Mathers, (416) 675-6777 ext. 4721, ; For
Media, Catherine Melville, (416) 675-6777 ext. 2265,
Copyright
Grafico Azioni Mds (NYSE:MDZ)
Storico
Da Giu 2024 a Lug 2024
Grafico Azioni Mds (NYSE:MDZ)
Storico
Da Lug 2023 a Lug 2024
Notizie in Tempo Reale relative a Mds (Borsa di New York (NYSE)): 0 articoli recenti
Più Mds Articoli Notizie